Table 1 RSV test positivity in MarketScan Commercial Claims and Medicare Supplemental Databases and the National Respiratory and Enteric Virus Surveillance System (2011–2019), total and stratified by tests type
Variables | Test positivity, % | ||||||||
|---|---|---|---|---|---|---|---|---|---|
MarketScan* | NREVSS | ||||||||
All tests (N = 1,418,020, 13.4%) | Antibody (N = 32,900, 18.5%) | Antigen (N = 786,065, 21.2%) | Viral culture (N = 66,696, 1.1%) | PCR (N = 532,359, 3.1%) | All tests (N = 7,079,301, 9.2%) | Antigen (N = 1,983,441, 16.0%) | Viral culture (N = 471,707, 2.8%) | PCR (N = 4,624,152, 7.9%) | |
Calendar year | |||||||||
2011 | 16.1 | 19.2 | 21.0 | 1.6 | 2.2 | 13.0 | 17.3 | 3.5 | 8.7 |
2012 | 16.0 | 19.9 | 22.0 | 1.2 | 1.8 | 13.2 | 17.3 | 3.4 | 10.2 |
2013 | 15.3 | 19.8 | 22.4 | 1.2 | 2.3 | 12.2 | 16.9 | 3.4 | 9.7 |
2014 | 11.9 | 15.1 | 19.1 | 0.9 | 1.9 | 8.8 | 13.6 | 2.3 | 7.0 |
2015 | 13.7 | 16.8 | 21.1 | 0.9 | 2.5 | 9.6 | 15.7 | 2.6 | 7.9 |
2016 | 14.1 | 19.6 | 22.2 | 0.8 | 2.8 | 8.7 | 14.6 | 1.7 | 7.5 |
2017 | 12.6 | 18.1 | 20.7 | 1.0 | 2.8 | 8.5 | 14.8 | 1.3 | 7.5 |
2018 | 11.0 | 18.7 | 21.2 | 0.7 | 3.6 | 8.7 | 15.2 | 1.8 | 7.8 |
2019 | 11.1 | 16.3 | 20.9 | 0.3 | 4.8 | 8.5 | 14.3 | 2.3 | 7.9 |
Calendar quarter | |||||||||
1 | 17.1 | 22.4 | 24.1 | 1.6 | 4.0 | 13.8 | 20.8 | 4.5 | 11.3 |
2 | 4.6 | 8.0 | 9.7 | 0.5 | 0.9 | 3.5 | 6.3 | 1.1 | 2.7 |
3 | 3.0 | 6.1 | 7.9 | 0.2 | 0.6 | 2.0 | 5.7 | 0.3 | 1.0 |
4 | 15.4 | 18.6 | 22.6 | 1.3 | 4.7 | 11.1 | 17.0 | 3.1 | 9.3 |
HHS region | |||||||||
Region 1—Boston | 11.0 | 18.9 | 23.0 | 0.7 | 2.7 | 7.8 | 8.8 | 1.3 | 7.4 |
Region 2—New York | 7.6 | 13.0 | 18.9 | 1.8 | 3.0 | 8.1 | 14.9 | 4.5 | 6.9 |
Region 3—Philadelphia | 12.1 | 16.1 | 21.4 | 0.9 | 3.5 | 9.8 | 15.5 | 3.6 | 7.8 |
Region 4—Atlanta | 14.7 | 17.9 | 20.3 | 0.6 | 2.7 | 10.1 | 13.7 | 1.2 | 7.5 |
Region 5—Chicago | 11.7 | 22.8 | 22.2 | 1.1 | 3.4 | 9.6 | 19.8 | 4.6 | 7.5 |
Region 6—Dallas | 16.1 | 17.6 | 21.1 | 1.2 | 3.7 | 12.5 | 19.5 | 3.2 | 9.6 |
Region 7—Kansas City | 15.4 | 21.0 | 22.1 | 1.3 | 3.9 | 11.2 | 19.5 | 1.1 | 8.0 |
Region 8—Denver | 13.5 | 22.1 | 25.0 | 0.8 | 3.3 | 10.5 | 17.6 | 1.2 | 9.4 |
Region 9—San Francisco | 10.9 | 22.1 | 21.1 | 1.0 | 2.0 | 9.0 | 16.0 | 1.0 | 7.4 |
Region 10—Seattle | 9.4 | 25.4 | 23.6 | 0.5 | 2.5 | 8.5 | 14.0 | 2.1 | 7.8 |
Unknown | 14.8 | 18.2 | 22.1 | 0.6 | 3.4 | ||||
Age group | |||||||||
0 | 22.9 | 22.6 | 24.6 | 10.2 | 13.2 | ||||
1 | 19.0 | 17.8 | 21.1 | 4.0 | 8.8 | ||||
2 | 17.1 | 17.2 | 20.1 | 3.6 | 6.8 | ||||
3 | 12.6 | 15.2 | 16.9 | 1.4 | 4.5 | ||||
4 | 8.3 | 11.5 | 13.1 | 1.0 | 2.9 | ||||
5–9 | 3.0 | 5.6 | 7.8 | 0.5 | 1.1 | ||||
10–14 | 0.7 | 3.9 | 3.4 | 0.1 | 0.3 | ||||
15–17 | 0.4 | 3.9 | 3.2 | 0.1 | 0.2 | ||||
18–30 | 0.7 | 5.9 | 4.7 | 0.1 | 0.4 | ||||
31–40 | 0.7 | 3.2 | 4.7 | 0.1 | 0.4 | ||||
41–50 | 0.6 | 1.6 | 2.1 | 0.2 | 0.6 | ||||
51–64 | 0.8 | 1.1 | 1.6 | 0.1 | 0.8 | ||||
> = 65 | 1.3 | 1.4 | 1.0 | 0.2 | 1.6 | ||||
Clinical setting | |||||||||
Inpatient visit | 4.7 | 12.3 | 10.6 | 0.8 | 3.1 | ||||
Emergency visit | 11.6 | 15.7 | 17.2 | 3.1 | 6.0 | ||||
Outpatient visit | 14.2 | 19.9 | 22.1 | 0.8 | 2.2 | ||||
Indication for testing | |||||||||
Severe complication | 6.4 | 16.3 | 18.1 | 0.5 | 3.8 | ||||
LRTI | 37.5 | 35.3 | 44.4 | 4.6 | 14.1 | ||||
Asthma exacerbation | 3.5 | 2.6 | 4.8 | 1.2 | 2.6 | ||||
URTI | 5.0 | 6.4 | 6.9 | 0.5 | 1.8 | ||||
Respiratory symptoms | 6.7 | 13.3 | 13.2 | 0.8 | 1.8 | ||||
Others (e.g., flu/RSV infection) | 9.1 | 17.4 | 20.6 | 0.4 | 1.5 | ||||